3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
olaparib
1
cc-486
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Pathologic Complete Response
×
cc-486
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA